Anaptysbio (ANAB) Cash from Operations Growth (5y) (2021 - 2026)
Anaptysbio (ANAB) Cash from Operations Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn |
| 10 | Anaptysbio | 1.56 Bn | 1.27 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.24% |
| Dec 31, 2025 | 21.13% |
| Sep 30, 2025 | -9.96% |
| Jun 30, 2025 | -15.46% |
| Mar 31, 2025 | 6.67% |
| Dec 31, 2024 | -33.36% |
| Sep 30, 2024 | 14.51% |
| Jun 30, 2024 | -6.56% |
| Mar 31, 2024 | -18.27% |
| Dec 31, 2023 | -22.82% |
| Sep 30, 2023 | -19.67% |
| Jun 30, 2023 | -23.41% |
| Mar 31, 2023 | -14.51% |
| Dec 31, 2022 | -17.31% |
| Sep 30, 2022 | -35.48% |
| Jun 30, 2022 | -55.65% |
| Mar 31, 2022 | -21.01% |
| Dec 31, 2021 | -35.35% |
| Sep 30, 2021 | -17.92% |
| Jun 30, 2021 | 41.87% |